MARKET IS CLOSED
Loading latest tickers...

Market Indices

S&P 500
$7,801.77
-0.22%
NASDAQ 100
$31,160.08
-0.21%
DOW JONES
$51,180.00
-0.66%
NASDAQ Composite
$27,538.69
-0.22%
RUSSELL 2000
$2,777.00
-1.29%
CBOE VIX
$15.08
+0.47%

Sector Heatmap

Technology-0.30%
Financials-0.48%
Healthcare+1.03%
Consumer Cycl-0.32%
Consumer Staples-0.12%
Energy-0.58%
Industrials-2.18%
Materials-1.51%
Real Estate-1.29%
Utilities-0.02%
Comm Services-0.35%

RGNT — Regentis Biomaterials Ltd.

NYSE American

Regentis Biomaterials Ltd.

CompareBack to Screener
$1.63
-0.02(-1.21%)
O
1.64
H
1.69
L
1.63
V
14.67K
⏱️ End-of-day dataAs of Oct 7, 2026

Chart

About RGNT

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

IndustryCommon Stock
SectorNot available
IPO DateDec 4, 2025
Employees8
Stock ExchangeNYSE American
Ticker SymbolRGNT

Key Financial Statistics

Market Cap$12.99M
P/E RatioN/A
Dividend YieldNone
EPSN/A
BetaN/A
52-Week Range$1.23 - $15.50
52-Week Avg Volume1.57M
VWAP$1.66
Transactions198
Total Recorded Bars211 days